Abstract Interleukin-1 receptor-associated kinase 4 (IRAK4) is a central kinase in Toll-like receptor (TLR)/MYD88 signaling and represents an emerging therapeutic target in inflammatory diseases and B-cell malignancies. Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) frequently harbors MYD88 mutations that drive constitutive MYD88/IRAK4 signaling activation and are associated with poor clinical outcomes.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Wen-hao
Contact Wen-hao, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack